Work

Abstract CT504: A phase 1 clinical trial to evaluate safety, tolerability, pharmacokinetics (PK) and efficacy of D-1553, a novel KRASG12C inhibitor, in patients with advanced or metastatic solid tumor harboring KRASG12C mutation

Year: 2022

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2022-ct504

Authors: Timothy Price, Jaspreet Grewal, Afaf Abed, Melissa Moore, Yu-Min Yeh, Shirish Gadgeel, Gary Richardson, Craig Underhill, Vinod Ganju, Keun-Wook Lee, Seok Jae Huh, Sang-We Kim, Chih-Hsin Yang, Yuh-Min Chen, Ziyong Xiang, Zhe Shi, Yaolin Wang, Ling Zhang, Michael Millward

Institutions: Queen Elizabeth Hospital, Norton Healthcare, Linear Clinical Research, St Vincent's Hospital Melbourne, National Cheng Kung University Hospital, Henry Ford Hospital, Cabrini Hospital, Albury Wodonga Health, Seoul National University, Dong-A University Hospital, Asan Medical Center, National Taiwan University Hospital, Taipei Veterans General Hospital, InventisBio Co., Ltd. (China)

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4282976626

Cites:

Cited by: 4

Related to: 10